e0475  IMPACT OF ANAEMIA ON DEVELOPMENT OF CONTRASTINDUCED ACUTE KIDNEY INJURY AKI AFTER PERCUTANEOUS CORONARY INTERVENTIONS

doi:10.1136/hrt.2010.208967.475

Li Wenhua, Li Dongye, Xu Tongda, Xia Yong, Department of Cardiology, Affiliated Hospital of Ouzo Medical College, 221002 Xuzhou

**Objective** The aim of the present study was to assess the influence of anaemia on development of contrast-induced acute kidney injury (AKI) after percutaneous coronary intervention.

**Methods** The subject group consisted of 1026 patients who had undergone coronary intervention procedure between January 1, 2008 and October 31, 2009. A nonionic, low osmolality contrast agent was used in our laboratory at this time. Serum creatinine values were measured before and within 48 h of administration of contrast agents. Contrast-induced nephropathy was defined as an increase of ≥0.5 mg/dl or ≥3% in serum creatinine concentration over baseline within 48 h of angiography. Anemia as haemoglobin (Hgb) 120 g/l in women and 130 g/l in men.

**Results** Among the 1026 patients studied, 32 (3.1%) experienced AKI after procedure. AKI occurred in 6.3% of the anaemic patients and 2.2% of the non-anaemic patients (p=0.05). Multivariate logistic regression analysis found that baseline creatinine clearance and baseline haemoglobin were independent predictors of AKI. When presence of anaemia was introduced into the multivariate model instead of baseline haemoglobin, it was also showed a significant association with AKI.

**Conclusion** Anemia increases the incidence of AKI in patients with moderate renal dysfunction. Patients with both preexisting renal insufficiency and anaemia are at high risk of AKI. Baseline creatinine clearance and baseline haemoglobin (or anaemia) are independent predictors of AKI.

e0476  OBSERVATION THE CHANGE OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN LEVELS IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY AND PERCUTANEOUS CORONARY INTERVENTION

doi:10.1136/hrt.2010.208967.476

Li Wenhua, Han Fei, Li Dongye, Xu Tongda, Zhang Yabin, Department of Cardiology, Affiliated Hospital of Xuzhou Medical College, Jiangsu, China

**Objective** To observe the level of neutrophil gelatinase-associated lipocalin (NGAL) in patients undergoing coronary angiography (CAG) and/or percutaneous coronary intervention (PCI) procedure before and after operation and to explore NGAL value in predicting of contrast-induced acute renal injury (CI-AKI).

**Methods** 60 patients undergoing CAG and/or PCI were enrolled in this study. Serum creatinine (Scr) and urinary NGAL were detected at different time points before and after operation.

**Results** Of all 60 patients, the change of the Scr level were not statistically significant (p>0.05), there were no case of CI-AKI. Scr level of urine NGAL at 6, 12, 24 h after operation was significantly increased after coronary intervention compared with baseline (p<0.05).

**Conclusion** Urinary NGAL has been significantly increased after coronary interventional therapy without the change of Scr levels. Urinary NGAL might be an early biomarker of prediction CI-AKI better than Scr.

e0477  OBESITY IS ASSOCIATED WITH INCREASED NONTARGET LESION REvascularization AFTER PERCUTANEOUS CORONARY INTERVENTION WITH DRUGELUTING STENTS

doi:10.1136/hrt.2010.208967.477

Wang Zhijian, Zhou Yue, Zhao Yongjun, Shi Dongmei, Liu Yuyang, Gao Fei, Anzhen Hospital, Beijing

**Background** Obesity is a major risk factor for developing coronary artery disease. It is less clear whether obesity accelerates progression of disease among those with established coronary disease.

**Objective** To evaluate the effect of obesity on repeat revascularization for target and nontarget lesions in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).

**Methods** We studied 4,972 patients between January 2004 and December 2006. Patients were divided into three groups according to body mass index (BMI): normal (BMI 50 kg/m², n=1, 213). Median follow-up was 26 (IR 20–33) months.

**Results** There was no significant difference in the cumulative incidence of target lesion revascularisation (TLR) among normal-weight, overweight and obese patients (6.8% vs 5.4% vs 6.3%; p=0.186). In contrast, the incidence of nontarget lesion revascularisation (nonTLR) was significantly higher in obese patients compared with normal-weight and overweight populations (5.6% vs 5.9% vs 5.7%; p=0.001). Multivariate analysis showed that obesity was independently associated with a higher risk of nonTLR in patients without statins treatment (HR 1.55, 95% CI 1.03 to 2.28; p=0.057), but not in patients with concomitant statins treatment (HR 1.29, 95% CI 0.82 to 2.03; p=0.263).

**Conclusions** Among patients undergoing PCI with DES, obesity was not associated with TLR, but was associated with a higher risk of nonTLR. Statins use may attenuate this adverse effect of obesity on atherosclerotic progression.

e0478  PIOGLITAZONE ATTENUATES PROINFLAMMATORY STATE IN NONDIABETIC PATIENTS AFTER CORONARY DRUGELUTING STENT IMPLANTATION

doi:10.1136/hrt.2010.208967.478


**Objectives** The inflammatory response after DES placement has recently emerged as a major concern. We investigated the proinflammatory state on circulating peripheral blood mononuclear cells (MNC) after coronary polymer-based drug-eluting stent (DES) implantation in non-diabetic patients, and the benefit of pioglitazone (PIO), a peroxisome proliferator-activated receptor-γ (PPAR-γ) activator.

**Methods** Twenty-eight non-diabetic patients with acute coronary syndrome were randomly assigned to pioglitazone (n=14) or placebo (n=14) treatment. From the day after DES implantation, study medication (50 mg/d) for 12 weeks was given in addition to the standard drug treatment, the proinflammatory state on MNC was measured at baseline and after 12 weeks.

**Results** PIO treatment statistically decreased plasma concentrations of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), migration inhibitor factor (MIF), and matrix metalloproteinase-9 (MMP-9) compared with placebo (p=0.011, 0.008, 0.002 and 0.012, respectively), but standard therapy failed to restrain these factors. The mRNA expressions of IL-6, TNF-α, MIF and MMP-9 in circulating MNC decreased significantly in the PIO group (p=0.031, 0.012, 0.007 and 0.022, respectively). Interestingly, PIO prevented the loss of PPAR-γ expression in MNC after DES implantation (p=0.059). In addition, treatment with PIO enhanced the cytoplasmic IκB-α expression (p=0.003) and decreased the expression of the NF-κB p50 subunit and IκB-α (p=0.001 and 0.029, respectively). Concurrently, the NF-κB DNA binding activity in MNC was significantly inhibited by PIO treatment (p=0.004).

**Conclusion** The inflammatory responses did not reverse after implantation of DES despite standard drug therapy, whereas PIO treatment attenuated the proinflammatory state in circulating MNC. Our results suggest that PIO treatment sequentially acts through PPAR-γ activation, IκB-α induction, blockade of NF-κB activation, and inhibition of inflammatory cytokine expression. These findings demonstrate that PIO may have a novel direct protective role to modulate the local and circulating proinflammatory responses after coronary DES implantation.
Pioglitazone attenuates proinflammatory state in nondiabetic patients after coronary drugeluting stent implantation

Wu Yue, Zhang Weiping, Liu Weimin, Zhuo Xiaozhen, Wang Lijun and Yuan Zuyi

Heart 2010 96: A149
doi: 10.1136/hrt.2010.208967.478

Updated information and services can be found at:
http://heart.bmj.com/content/96/Suppl_3/A149.4

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Interventional cardiology (2933)
Clinical diagnostic tests (4779)
Drugs: cardiovascular system (8842)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/